BIOTECH
BIOTECH
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases...
Read moreBIOTECH
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...
Read moreBIOTECH
AUM Biosciences, SCG Cell Therapy, Blood And Hello Health Disclose Updates
AUM Biosciences, a Singapore-headquartered biotech company focused on precision oncology therapeutics, allotted shares worth $11.8...
Read moreBIOTECH
STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD
STALICLA and Firefly Neuroscience enterPartnership Agreement for the Development of Electroencephalogram (EEG) asa Biomarker for Subgroups of Patients with...
Read moreBIOTECH
Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.
This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was...
Read more